About D(2) dopamine receptor
D(2) dopamine receptor (DRD2) is a protein
from Homo sapiens identified by UniProt accession
P14416, 443 residues long.
MolForge cross-references it against 0 known binders and
811 disease associations.
Target properties
| Protein name | D(2) dopamine receptor |
| UniProt accession | P14416 |
| Gene | DRD2 |
| Organism | Homo sapiens |
| Length | 443 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (811)
Diseases linked to this target (Open Targets).
- schizophrenia · score 0.73
- bipolar disorder · score 0.72
- unipolar depression · score 0.71
- major depressive disorder · score 0.70
- attention deficit hyperactivity disorder · score 0.66
- Tourette syndrome · score 0.65
- Parkinson disease · score 0.62
- autism · score 0.62
- psychosis · score 0.61
- obsessive-compulsive disorder · score 0.61
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P14416-F1 | alphafold | PREDICTED | 72.45 | — |
Amino-acid sequence (443 residues)
MDPLNLSWYD DDLERQNWSR PFNGSDGKAD RPHYNYYATL LTLLIAVIVF GNVLVCMAVS REKALQTTTN YLIVSLAVAD LLVATLVMPW VVYLEVVGEW KFSRIHCDIF VTLDVMMCTA SILNLCAISI DRYTAVAMPM LYNTRYSSKR RVTVMISIVW VLSFTISCPL LFGLNNADQN ECIIANPAFV VYSSIVSFYV PFIVTLLVYI KIYIVLRRRR KRVNTKRSSR AFRAHLRAPL KGNCTHPEDM KLCTVIMKSN GSFPVNRRRV EAARRAQELE MEMLSSTSPP ERTRYSPIPP SHHQLTLPDP SHHGLHSTPD SPAKPEKNGH AKDHPKIAKI FEIQTMPNGK TRTSLKTMSR RKLSQQKEKK ATQMLAIVLG VFIICWLPFF ITHILNIHCD CNIPPVLYSA FTWLGYVNSA VNPIIYTTFN IEFRKAFLKI LHC
Explore D(2) dopamine receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets